<DOC>
	<DOCNO>NCT00000811</DOCNO>
	<brief_summary>This study compare 2 different treatment administer try prevent serious bacterial infection ( pneumonia ) HIV-positive child . A combination drug ( azithromycin plus atovaquone ) compare sulfamethoxazole-trimethoprim ( SMX/TMP ) alone . This study also evaluate long-term safety tolerance different drug . SMX/TMP commonly prescribe drug prevention bacterial infection . However , combination azithromycin atovaquone may safer effective SMX/TMP . This study compare 2 treatment .</brief_summary>
	<brief_title>A Study Compare Different Drugs Used Prevent Serious Bacterial Infections HIV-Positive Children</brief_title>
	<detailed_description>Although SMX/TMP remain drug choice PCP prophylaxis , drug sensitivity may limit use . Atovaquone demonstrate great safety SMX/TMP thus suitable candidate drug treatment prophylaxis PCP . Azithromycin , broad anti-microbial spectrum ( include mycoplasma atypical mycoplasma ) , attractive prophylactic agent use child HIV infection , due relative safety once-daily dose regimen . Therefore , combination atovaquone azithromycin may offer broad antimicrobial coverage great safety SMX/TMP . Patients randomize receive either SMX/TMP combination micronized atovaquone/azithromycin . Crossover alternative regimen may occur serious toxicity observe . Patients monitor occurrence serious bacterial infection PCP breakthrough , serious bacterial infection occurs , patient cross alternative regimen . Treatment continue 2 year last patient enrol . The first 30 patient undergo pharmacokinetic profile . Patients follow every 4 week first 4 month , every 8 week thereafter . [ AS PER AMENDMENT 05/28/99 : This study close infant child age 19 month old 2/15/99 ; study open infant age 3 18 month ( Stage II ) . Patients age 24 month old time Stage I closure end-of-study evaluation longer follow protocol . Patients less 24 month age time Stage I closure allow continue current version protocol . Enrollment child age 3 18 month continue 50 subject randomize . Because Stage II unblinded study , patient le 24 month age currently enrol Version 4.0 study medication regimen unblinded atovaquone dose increase . ]</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are HIVpositive . Are age 3 month 18 month ( consent parent guardian require ) . ( This study change . In early version , patient 19 year old eligible . ) Are risk develop pneumonia need preventive treatment . Have CD4 count le 1,500 cells/mm3 1 year age CD4 count le 500 cells/mm3 1 2 year age . Exclusion Criteria Children eligible study : Have infection require treatment . Are allergic atovaquone , azithromycin , SMX/TMP . Have serious diarrhea 1 week .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>atovaquone</keyword>
</DOC>